MA47609A - Anticorps anti-il31 à usage vétérinaire - Google Patents

Anticorps anti-il31 à usage vétérinaire

Info

Publication number
MA47609A
MA47609A MA047609A MA47609A MA47609A MA 47609 A MA47609 A MA 47609A MA 047609 A MA047609 A MA 047609A MA 47609 A MA47609 A MA 47609A MA 47609 A MA47609 A MA 47609A
Authority
MA
Morocco
Prior art keywords
antibodies
veterinary use
veterinary
Prior art date
Application number
MA047609A
Other languages
English (en)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MA47609A publication Critical patent/MA47609A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA047609A 2017-02-24 2018-02-09 Anticorps anti-il31 à usage vétérinaire MA47609A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762463543P 2017-02-24 2017-02-24
PCT/US2017/023788 WO2018156180A1 (fr) 2017-02-24 2017-03-23 Anticorps anti-il31 à usage vétérinaire

Publications (1)

Publication Number Publication Date
MA47609A true MA47609A (fr) 2020-01-01

Family

ID=63245488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047609A MA47609A (fr) 2017-02-24 2018-02-09 Anticorps anti-il31 à usage vétérinaire

Country Status (11)

Country Link
US (7) US10093731B2 (fr)
EP (1) EP3585429A4 (fr)
JP (3) JP7277370B2 (fr)
KR (1) KR20190127703A (fr)
CN (2) CN117603350A (fr)
AU (2) AU2018224711B2 (fr)
BR (1) BR112019017308A2 (fr)
CA (1) CA3053525A1 (fr)
MA (1) MA47609A (fr)
MX (1) MX2024012304A (fr)
WO (1) WO2018156180A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US11207390B2 (en) * 2017-03-07 2021-12-28 Universität Zürich Treatment of pruritus in horses
CA3093709C (fr) 2018-03-16 2024-03-26 Zoetis Services Llc Vaccins peptidiques contre l'interleukine-31
KR20220002859A (ko) * 2018-12-19 2022-01-07 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 T 세포 림프종 및 백혈병에 대한 cd2/5/7 녹-아웃 항-cd2/5/7 키메라 항원 수용체 t 세포의 용도
EP4021499A4 (fr) * 2019-08-29 2024-08-07 Elanco US Inc. Anticorps anti-il31 à usage vétérinaire
CN114829396A (zh) * 2019-12-20 2022-07-29 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体和双特异性结合伴体
WO2021123089A1 (fr) 2019-12-20 2021-06-24 Intervet International B.V. Anticorps dirigés contre le récepteur alpha de l'interleukine-4 canine
CN115697403A (zh) * 2020-03-10 2023-02-03 迪赞纳生命科学公开有限公司 Il-6/il-6r抗体的组合物及其使用方法
PH12022552742A1 (en) * 2020-04-17 2024-03-25 Zoetis Services Llc Canine antibody variants
EP4136109A1 (fr) * 2020-04-17 2023-02-22 Zoetis Services LLC Variants d'anticorps félin
CA3173864A1 (fr) * 2020-04-22 2021-10-28 Shyr Jiann Li Anticorps anti-il31 a action prolongee a usage veterinaire
WO2022010652A1 (fr) 2020-07-10 2022-01-13 Invetx Inc. Compositions permettant d'augmenter la demi-vie d'un agent thérapeutique chez les félins et procédés d'utilisation
US12577310B2 (en) 2020-10-15 2026-03-17 Intervet Inc. Caninized antibodies to canine interleukin-31 receptor alpha
EP4247848A4 (fr) * 2020-11-23 2025-10-01 Scout Bio Inc Molécules de liaison à l'antigène et leurs utilisations
US20220273793A1 (en) * 2021-02-22 2022-09-01 Zoetis Services Llc Horse il-31 induced pruritus model
EP4388006A1 (fr) 2021-08-20 2024-06-26 Intervet International B.V. Protéines de fusion homodimères pour le traitement de la dermatite atopique
US20250340654A1 (en) 2021-12-16 2025-11-06 Intervet Inc. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2024145280A2 (fr) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides à liaison modifiée au récepteur fc néonatal (fcrn) et procédés d'utilisation
EP4642795A2 (fr) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides à liaison modifiée au récepteur fc néonatal (fcrn) et procédés d'utilisation
KR20250151402A (ko) 2023-01-20 2025-10-21 인베티엑스 인코포레이티드 반려 동물에서 사용하기 위한 이중특이적 결합제
CN120897928A (zh) 2023-02-13 2025-11-04 英特维特国际股份有限公司 针对犬il-4的犬抗体
JP2026508149A (ja) 2023-02-13 2026-03-10 インターベット インターナショナル ベー． フェー． イヌｉｌ－１３に対するイヌ抗体
CN120865402A (zh) * 2023-11-27 2025-10-31 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
CN118667001B (zh) * 2024-07-16 2025-05-06 华中农业大学 一种抗犬il-31的单克隆抗体及其应用
CN120209126B (zh) * 2025-05-28 2025-09-16 中国医学科学院医学生物学研究所 人偏肺病毒单克隆抗体及其应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
CA2163976C (fr) 1993-05-28 2010-06-29 Didier J. Leturcq Methodes et compositions pour inhiber l'activation de cellules via cd14
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2401491C (fr) 2000-03-03 2011-07-05 Kyowa Kirin Co., Ltd. Anticorps fixateur ccr4 et ses utilisations diagnostiques et therapeutiques
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1485126A4 (fr) 2001-12-21 2007-03-21 Idexx Lab Inc Domaines variable d'immunoglobuline canine, anticorps caninises, et procede de production et d'utilisation associes
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
MXPA05003884A (es) 2002-10-16 2005-10-05 Euro Celtique Sa Anticuerpos que enlazan polipeptidos ca 125/0772p a celulas asociadas y metodos de uso de los mismos.
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1671642A1 (fr) 2004-12-15 2006-06-21 Universite D'angers Composés contenant des (ant)agonistes de l'oncostatin M (OSM), IL-31 et IFN-gamma pour moduler la migration et fonction de keratinocytes au moyen d'un recepteur comprenant l'OSMRbeta comme sousunité, et applications correspondantes
AU2006207945B2 (en) 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
CA2594490A1 (fr) 2005-02-14 2006-08-24 Zymogenetics Inc. Methodes de traitement d'affections de la peau en employant un antagoniste de il-31ra
EP1856150A2 (fr) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methodes de traitement des maladies mediees par des cellules positives a l'egard de l'antigene lymphocytaire cutane
JP2008532559A (ja) 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
KR101446989B1 (ko) 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
RU2444528C2 (ru) 2005-05-06 2012-03-10 Займоджинетикс, Инк. Моноклональные антитела против il-31 и способы применения
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
CN1896229A (zh) 2005-06-29 2007-01-17 北京天广实生物技术有限公司 一种新型抗cd20嵌合抗体的制备及其用途
JP5289963B2 (ja) 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗ａｄｄｌモノクローナル抗体およびその使用
CA2636288C (fr) 2006-01-10 2015-02-24 Zymogenetics, Inc. Procedes de traitement de la douleur et de l'inflammation dans les tissus neuronaux au moyen d'antagonistes de l'il-31
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP2061496A2 (fr) 2007-01-10 2009-05-27 Zymogenetics, Inc. Méthodes d'utilisation de il-31 pour le traitement de l'hyper-réactivité des voies respiratoires et de l'asthme
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
EP2384326B1 (fr) 2008-08-20 2014-04-23 Zoetis LLC Composés pyrrolo[2,3-d]pyrimidines
US8337842B2 (en) 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
US20110287454A1 (en) 2008-11-25 2011-11-24 Cornell University Methods for monoclonal antibody production
WO2011065935A1 (fr) 2009-11-24 2011-06-03 Cornell University Procédés de production d'anticorps monoclonaux
AU2013203075A1 (en) 2008-11-28 2013-05-02 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US20110165063A1 (en) 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010117448A2 (fr) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Immunocytokines chimériques et leurs procédés d'utilisation
CN102459339A (zh) 2009-06-22 2012-05-16 派特塞尔有限公司 药物制剂
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
US9255925B2 (en) 2010-10-20 2016-02-09 Medical Diagnostic Laboratories, Llc ELISA detection of urine DEK to predict and diagnose bladder cancer in humans
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
ES2667568T3 (es) 2011-04-25 2018-05-11 Daiichi Sankyo Company, Limited Anticuerpo anti-B7-H3
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
CN103732621B (zh) 2011-05-06 2020-04-24 內克斯威特澳大利亚私人有限公司 抗神经生长因子抗体及其制备和使用方法
EP2710040B1 (fr) 2011-05-19 2017-07-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-her3 humain et leurs utilisations
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CN113788897A (zh) 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US20160102127A1 (en) 2013-05-27 2016-04-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Targeted modulation of macrophages
CN110511279B (zh) * 2013-05-30 2024-03-29 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
TW201537175A (zh) 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
US20150004161A1 (en) 2013-07-01 2015-01-01 University Of Maryland Fc Coupled Compositions and Methods of Their Use
WO2015042596A1 (fr) * 2013-09-23 2015-03-26 Kindred Biosciences, Inc Traitement de la dermite atopique chez des animaux non humains
WO2015067755A2 (fr) 2013-11-07 2015-05-14 Novo Nordisk A/S Nouvelles méthodes et nouveaux anticorps destinés au traitement d'une coagulopathie
WO2015086830A1 (fr) 2013-12-13 2015-06-18 Delenex Therapeutics Ag Polypeptides pénétrant dans la peau
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3250589A4 (fr) 2015-01-29 2018-06-20 Nexvet Australia Pty Ltd Agents diagnostiques et thérapeutiques
CN104710528B (zh) * 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2016170176A1 (fr) * 2015-04-22 2016-10-27 Curevac Ag Composition contenant de l'arn pour le traitement de maladies tumorales
WO2015151079A2 (fr) 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire
WO2017025698A1 (fr) 2015-08-11 2017-02-16 Queen Mary University Of London Anticorps bispécifiques, clivables
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
TWI780045B (zh) * 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
US11649283B2 (en) 2016-04-15 2023-05-16 Immunext, Inc. Anti-human vista antibodies and use thereof
US10836796B2 (en) 2016-04-20 2020-11-17 Hangzhou Dac Biotech Co., Ltd. Derivatives of amanita toxins and their conjugation to a cell binding molecule
EP3526246A1 (fr) 2016-10-17 2019-08-21 Vetoquinol SA Région constante modifiée d'un anticorps
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018156367A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
EP3606922A4 (fr) 2017-04-06 2021-03-03 Hangzhou Dac Biotech Co., Ltd Conjugaison d'un médicament cytotoxique avec une bis-liaison
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
BR112019021812A2 (pt) 2017-04-21 2020-05-26 Kindred Biosciences, Inc. Molécula receptora de il4/il13 para uso veterinário
EP3483180A1 (fr) 2017-11-14 2019-05-15 Affilogic Molécules multispécifiques
MX2020006105A (es) 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
MX2020006192A (es) 2017-12-31 2020-08-20 Hangzhou Dac Biotech Co Ltd Un conjugado de un analogo de tubulisina con enlazadores ramificados.
AU2019234220B2 (en) 2018-03-16 2025-09-11 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
WO2019183449A1 (fr) 2018-03-23 2019-09-26 North Carolina State University Méthodes et compositions pour troubles allergiques
WO2019200022A1 (fr) 2018-04-11 2019-10-17 Inhibrx, Inc. Produits de recombinaison de polypeptides plurispécifiques comprenant une fixation à cd3 contrainte et méthodes d'utilisation associées
MX2020014083A (es) 2018-07-05 2021-04-12 Hangzhou Dac Biotech Co Ltd Un derivado de dímero de pirrolobenzodiazepina (pbd) reticulado y sus conjugados.
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
CN113195487A (zh) 2018-10-12 2021-07-30 杭州多禧生物科技有限公司 2，3-二氨基琥珀酰基偶联物连接子
BR112021006977A2 (pt) 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
WO2020086886A1 (fr) 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Molécule du récepteur d'il4/il13 à usage vétérinaire
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
AU2019416344A1 (en) 2018-12-27 2021-07-01 Elanco Us Inc. IgG Fc variants for veterinary use
AU2020205073A1 (en) 2019-01-03 2021-08-19 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20230057350A1 (en) 2019-01-31 2023-02-23 Hangzhou Dac Biotech Co., Ltd. A conjugate of an amanita toxin with branched linkers
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
CN120053667A (zh) 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
AU2020301115B2 (en) 2019-06-24 2024-05-23 Hangzhou Dac Biotech Co., Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
MX2021015887A (es) 2019-06-24 2022-03-22 Hangzhou Dac Biotech Co Ltd Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
EP4021499A4 (fr) 2019-08-29 2024-08-07 Elanco US Inc. Anticorps anti-il31 à usage vétérinaire
WO2021115240A1 (fr) 2019-12-13 2021-06-17 四川科伦博泰生物医药股份有限公司 Anticorps anti-tslp et utilisations de celui-ci
CN114829396A (zh) 2019-12-20 2022-07-29 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体和双特异性结合伴体
JP2023513952A (ja) 2020-02-19 2023-04-04 アディボ ゲーエムベーハー 改変Ｆｃ領域
MX2022011335A (es) 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
PH12022552742A1 (en) 2020-04-17 2024-03-25 Zoetis Services Llc Canine antibody variants
US20240270819A1 (en) 2020-04-22 2024-08-15 Elanco Us Inc. Il4/il13 receptor molecules for veterinary use
CA3173864A1 (fr) 2020-04-22 2021-10-28 Shyr Jiann Li Anticorps anti-il31 a action prolongee a usage veterinaire
US20230241241A1 (en) 2020-06-19 2023-08-03 Hangzhou Dac Biotech Co., Ltd. Conjugates of a cell-binding molecule with camptothecin analogs
WO2022010652A1 (fr) 2020-07-10 2022-01-13 Invetx Inc. Compositions permettant d'augmenter la demi-vie d'un agent thérapeutique chez les félins et procédés d'utilisation
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
IL300694A (en) 2020-09-01 2023-04-01 Chugai Pharmaceutical Co Ltd A pharmaceutical preparation for the prevention and/or treatment of dialysis pruritus that includes an IL-31 antagonist as an active ingredient

Also Published As

Publication number Publication date
CN110769851B (zh) 2023-12-08
RU2019129618A3 (fr) 2021-06-23
JP2025138636A (ja) 2025-09-25
KR20190127703A (ko) 2019-11-13
AU2018224711A1 (en) 2019-09-05
US20200062840A1 (en) 2020-02-27
CN110769851A (zh) 2020-02-07
JP2023109811A (ja) 2023-08-08
EP3585429A4 (fr) 2020-12-02
US11697683B2 (en) 2023-07-11
AU2018224711B2 (en) 2024-11-14
EP3585429A1 (fr) 2020-01-01
US10150810B2 (en) 2018-12-11
US12435132B2 (en) 2025-10-07
JP7716441B2 (ja) 2025-07-31
US10093731B2 (en) 2018-10-09
CA3053525A1 (fr) 2018-08-30
US20240101660A1 (en) 2024-03-28
CN117603350A (zh) 2024-02-27
BR112019017308A2 (pt) 2020-04-14
MX2024012304A (es) 2024-11-08
US20190169285A1 (en) 2019-06-06
US11673946B2 (en) 2023-06-13
US20230365672A1 (en) 2023-11-16
RU2019129618A (ru) 2021-03-24
KR20240093562A (ko) 2024-06-24
JP7277370B2 (ja) 2023-05-18
US12448438B2 (en) 2025-10-21
US20180244766A1 (en) 2018-08-30
JP2020511123A (ja) 2020-04-16
WO2018156180A1 (fr) 2018-08-30
US20180244767A1 (en) 2018-08-30
US20210163587A1 (en) 2021-06-03
AU2025201182A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
MA47609A (fr) Anticorps anti-il31 à usage vétérinaire
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3589313A4 (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3423089A4 (fr) Anticorps anti-tigit
EP3359573A4 (fr) Marquage d'anticorps
MA50352A (fr) Anticorps multispécifiques
EP3334757A4 (fr) Anticorps anti-tigit
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3297671A4 (fr) Anticorps anti-ror1
MA49749A (fr) Anticorps anti-cd137
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
IL281717A (en) Antibody formulation
MA51134A (fr) Anticorps anti-alpha-synucléine
MA52152A (fr) Anticorps
EP3349794A4 (fr) Anticorps anti-cd115
EP3831851A4 (fr) Anticorps anti-btla